Back to Authors

Dalal, Jignesh

https://orcid.org/0000-0002-4418-4919

Mayo Clinic

Rainbow Babies & Children's Hospital

Citations 12

Inferior Access to Allogeneic Transplant in Disadvantaged Populations: A CIBMTR Analysis
Paulson, Kristjan, Brazauskas, Ruta , He, Naya, Szwajcer, David , Seftel, Matthew D. , Dalal, Jignesh , Hahn, Theresa , Bonfim, Carmem , Khera, Nandita , Burns, Linda J. , Mau, Lih‐Wen, Saber, Wael , Atsuta, Yoshiko , Majhail, Navneet S.

Blood | October 11, 2019 | Volume: 128 | Issue: 22 | Pages: 842-842

10.1182/blood.v128.22.842.842 Get It

Abstract Introduction: Allogeneic stem cell transplant is an intensive procedure, offered in a limited number of medical centres. We sought to describe how sociodemographic variables impacted access to transplant across the United States, and if disadvantaged populations had inferior access to transplant. Methods: Data from the Surveillance, Epidemiology and End Results Program (SEER) and the Center for International Blood and Marrow Transplant Research (CIBMTR) was integrated to determine the rate of unrelated donor transplantation between 2000 and 2010 in each of the 612 counties included in the SEER registry. Patients under the age of 65 with AML, ALL, and MDS were included, and the analysis was restricted to unrelated donors due to limited availability of ZIP code in CIBMTR data. New incident cases were determined from SEER, and the number of transplants was determined from CIBMTR. The transplant rate was calculated (transplants performed divided by incident cases) for each county. County attributes (percent minority, rural/urban status, percentage below the poverty line, and median family size) were obtained from US Census data. Poisson regression was used to describe how county attributes impacted transplant rates. Transplant rates were calculated separately for AML, White residents, and pediatric ALL. Results: 3147 patients were identified in the CIBMTR dataset that met inclusion criteria. The estimated ZIP code completeness was 75%. There were 30,468 new incident diagnoses of ALL, AML, and MDS. For AML, patients from rural areas (less than 20,000 residents) and patients from areas with higher poverty levels had lower transplant rates (Table 1). Minority status and family size did not impact transplant rate. In regression models, higher levels of poverty remained associated with lower transplant rates, while rurality did not (Table 2). The results were similar among White residents. In contrast, in pediatric ALL, no county attributes (poverty, rurality, percent minority, and family size) were significantly associated with a difference in transplant rate (Table 1). However, numbers of transplants were smaller, limiting power. Discussion: Patients with AML from disadvantaged areas had lower rates of unrelated donor transplant. While patients from disadvantaged areas were also more likely to be non-White, and non-White Americans are less likely to have an available unrelated donor, this difference was also seen in White Americans from disadvantaged areas. This suggests the lower transplant rate is due impaired access to transplant. Poverty rate was the most important predictor of transplant rate. The results of this study suggest that improving access to transplant in disadvantaged populations should be a priority for health care administrators. Based on these results, approximately 2500 Americans do not undergo allogeneic transplant annually due to inferior access associated with higher poverty rates. Table 1 Univariate Analysis Table 1. Univariate Analysis Table 2 Acute Myeloid Leukemia, Regression Model * Metropolitan = county > 50,000 people, micropolitan = county > 20,000, rural county < 20,000. Table 2. Acute Myeloid Leukemia, Regression Model. / * Metropolitan = county > 50,000 people, micropolitan = county > 20,000, rural county < 20,000. Disclosures Hahn: Novartis: Equity Ownership; NIH: Research Funding.
Impact of pre‐transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation
El‐Jawahri, Areej , Chen, Yi‐Bin, Brazauskas, Ruta , He, Naya, Lee, Stephanie J. , Knight, Jennifer M. , Majhail, Navneet S. , Buchbinder, David , Schears, Raquel M. , Wirk, Baldeep , Wood, William A. , Ahmed, Ibrahim , Aljurf, Mahmoud , Beattie, Sara , Dandoy, Christopher E. , Díaz, Miguel Ángel , D’Souza, Anita , Freytes, César O. , Gajewski, James , Hashmi, Shahrukh K. , Jakubowski, Ann A. , Kamble, Rammurti T., Kindwall‐Keller, Tamila L. , Lazarus, Hilard M., Malone, Adriana K. , Marks, David I. , Meehan, Kenneth R., Olsson, Richard F. , Rizzieri, David A. , Steinberg, Amir , Speckhart, Dawn, Szwajcer, David , Schoemans, Hélène , Seo, Sachiko , Üstün, Celalettin , Dalal, Jignesh , Sales‐Bonfim, Carmem, Khera, Nandita , Hahn, Theresa , Saber, Wael , Chen, Yi‐Bin , Szer, Jeff , Battiwalla, Minoo , Gergis, Usama , Savani, Bipin N. , Atsuta, Yoshiko , D'Souza, Anita , Olsson, Richard F , Majhail, Navneet S , Knight, Jennifer M , Diaz Perez, Miguel Angel , Dandoy, Christopher E , Lee, Stephanie J , Wood, William A

Cancer | January 19, 2017 | Volume: 123 | Issue: 10 | Pages: 1828-1838

10.1002/cncr.30546 Get It

BACKGROUNDTo evaluate the impact of depression before autologous and allogeneic hematopoietic cell transplantation (HCT) on clinical outcomes post‐transplantation.METHODSWe analyzed data from the Center for International Blood and Marrow Transplant Research to compare outcomes after autologous (n = 3786) or allogeneic (n = 7433) HCT for adult patients with hematologic malignancies with an existing diagnosis of pre‐HCT depression requiring treatment versus those without pre‐HCT depression. Using Cox regression models, we compared overall survival (OS) between patients with or without depression. We compared the number of days alive and out of the hospital in the first 100 days post‐HCT using Poisson models. We also compared the incidence of grade 2‐4 acute and chronic graft‐versus‐host disease (GVHD) in allogeneic HCT.RESULTSThe study included 1116 (15%) patients with pre‐transplant depression and 6317 (85%) without depression who underwent allogeneic HCT between 2008 and 2012. Pre‐transplant depression was associated with lower OS (hazard ratio [HR], 1.13; 95% confidence interval [CI], 1.04‐1.23; P = 0.004) and a higher incidence of grade 2‐4 acute GVHD (HR, 1.25; 95% CI, 1.14‐1.37; P < 0.0001), but similar incidence of chronic GVHD. Pre‐transplant depression was associated with fewer days‐alive‐and‐out‐of‐the hospital (means ratio [MR] = 0.97; 95% CI, 0.95‐0.99; P = 0.004). There were 512 (13.5%) patients with Pre‐transplant depression and 3274 (86.5%) without depression who underwent autologous HCT. Pre‐transplant depression in autologous HCT was not associated with OS (HR, 1.15; 95% CI, 0.98‐1.34; P = 0.096) but was associated with fewer days alive and out of the hospital (MR, 0.98; 95% CI, 0.97‐0.99; P = 0.002).CONCLUSIONPre‐transplant depression was associated with lower OS and higher risk of acute GVHD among allogeneic HCT recipients and fewer days alive and out of the hospital during the first 100 days after autologous and allogeneic HCT. Patients with pre‐transplant depression represent a population that is at risk for post‐transplant complications. Cancer 2017;123:1828–1838. © 2017 American Cancer Society.